Increased expression of hypoxia-inducible factor 1α in type I and type II endometrial carcinomas

Modern Pathology

Volumn 20, Issue 1, 2007, Pages 35-43

  Pansare, Vaishali ^a   Munkarah, Adnan R ^a   Schimp, Veronica ^a   Haitham Arabi, M ^a   Saed, Ghassan M ^a   Morris, Robert T ^a   Ali Fehmi, Rouba ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Endometrial carcinoma; High expression of HIF 1 ; Type I; Type II

Indexed keywords

ANTIBODY; C 1 ANTIBODY; DO7 ANTIBODY; H1 ALPHA67 ANTIBODY; HYPOXIA INDUCIBLE FACTOR 1ALPHA; K 2 ANTIBODY; KI 67 ANTIGEN; PARAFFIN; PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; AGGRESSIVENESS; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; ENDOMETRIUM CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORPHOLOGY; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; TISSUE MICROARRAY; TUMOR CELL; TYPE 1 ENDOMETRIUM CARCINOMA; TYPE 2 ENDOMETRIUM CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845710706     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800718     Document Type: Article

References (28)

1. Kurman RJ (ed). Blaustein's Pathology of the Female Genital Tract, 5th edn. Springer: New York, 2002, pp 501-560.
2. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by cellular oxygen tension. Proc Natl Acad Sci USA 1995;92:5510-5514.
3. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 1998;394:485-490.
4. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28:29-35.
5. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
6. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-289.
7. Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-117.
8. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-156.
9. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943.
10. Nordsmark M, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-1075.
11. Sivridis B, Giatromanolaki A, Gatter K, et al. Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002;95:1055-1063.
12. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor-1 alpha. Genes Dev 2000;14:34-44.
13. Mariani A, Sebo TJ, Webb MJ, et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect and Prev 2003;27:434-441.
14. Geisler JP, Geisler HE, Wiemann MC, et al. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol 1999;74:468-471.
15. Oreskovic S, Babic D, Kalafatic D, et al. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 2004;93:34-40.
16. Zhong H, De Marzo A, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5835.
17. Birner P, Schindl M, Obermair A, et al. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-1668.
18. Rouba Ali-Fehmi MC, Khalifeh I, Malone JM, et al. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 2003;98:1423-1429.
19. Mariani A, Sebo TJ, Katzmann JA, et al. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 2000;182:1535-1544.
20. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 2001;85:881-890.
21. Burri P, Djonov V, Aebersold DM, et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Gynecol Oncol Biol Phys 2003;56:494-501.
22. Acs G, Xu X, Chu C, et al. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer. 2004;100:2376-2386.
23. Semenza GL, Nejfelt MK, Chi SM, et al. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 1998;95:7987-7992.
24. Hui EP, Chan A, Pezella F, et al. Coexpression of hypoxia-inducible factors 1α and 2α, carbonic anhydarse IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-2604.
25. Giatromanolaki A, Koukourakis MI, Turley H, et al, Tumor and Angiogenesis Research Group. Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Mod Pathol 2006;19:701-707.
26. Salvesen HB, Iversen OE, Akslen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 1998;4:2779-2785.
27. Geisler JP, Geisler HE, Miller GA, et al. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Gynecol Oncol 1999;75:432-436.
28. Tashiro H, Isaacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur in their pathogenesis. Am J Pathol 1997;150:177-185.